首页> 外文期刊>The American Journal of Cardiology >Comparison of the Effect of Rosuvastatin 2.5 mg vs 20 mg on Coronary Plaque Determined by Angioscopy and Intravascular Ultrasound in Japanese With Stable Angina Pectoris (from the Aggressive Lipid-Lowering Treatment Approach Using Intensive Rosuvastatin for Vulnerable Coronary Artery Plaque [ALTAIR] Randomized Trial)
【24h】

Comparison of the Effect of Rosuvastatin 2.5 mg vs 20 mg on Coronary Plaque Determined by Angioscopy and Intravascular Ultrasound in Japanese With Stable Angina Pectoris (from the Aggressive Lipid-Lowering Treatment Approach Using Intensive Rosuvastatin for Vulnerable Coronary Artery Plaque [ALTAIR] Randomized Trial)

机译:比较2.5 mg和20 mg瑞舒伐他汀对稳定型心绞痛的日本人经血管镜和血管内超声测定的冠状动脉斑块的疗效比较(来自使用瑞舒伐他汀强化治疗降脂治疗冠状动脉斑块[ALTAIR]随机试验)

获取原文
获取原文并翻译 | 示例
           

摘要

Diminishing yellow color, evaluated by coronary angioscopy, is associated with plaque stabilization and regression. Our aim was to assess the effect of aggressive lipid-lowering therapy with rosuvastatin on plaque regression and instability. Thirty-seven patients with stable angina or silent myocardial ischemia who planned to undergo elective percutaneous coronary intervention and had angioscopic yellow plaques of grade 2 or more were randomized to high-dose (group H, 20 mg/day, n = 18) or low-dose (group L, 2.5 mg/day, n = 19) rosuvastatin therapy for 48 weeks. Yellow plaque was graded on a 4-point scale of 0 (white) to 3 (bright yellow) by angioscopy, and plaque volume was determined by intravascular ultrasound for plaques with a length of 5 to 15 mm. Color and volume were assessed at baseline and after 48 weeks by the investigators blinded to the rosuvastatin. dosage, and were compared between the 2 dosing groups. The level of low-density lipoprotein-cholesterol decreased from 130.3 +/- 25.5 mg/dl to 61.7 +/- 16.5 mg/dl (-50 +/- 19%: high intensity) in group H (p <0.001) and from 130.9 +/- 28.5 mg/dl to 89.7 +/- 29.0 mg/dl (-30 +/- 22%: moderate intensity). in group L (mean +/- SD, p <0.001). The average color grade of yellow plaques decreased from 2.0 to 1.5 in group H (p <0.001) and from 2.0 to 1.6 in group L (p <0.001) after 48 weeks. Plaque volume decreased significantly in group H but not in group L. The percent change in plaque volume was significantly larger in group H than in group L (p = 0.005). In conclusion, both high-dose and low-dose rosuvastatin increased plaque stability. However, high-dose rosuvastatin was more effective than low dose rosuvastatin in inducing plaque volume regression. (C) 2016 Elsevier Inc. All rights reserved.
机译:通过冠状动脉血管造影评估的黄色逐渐减少与斑块稳定和消退有关。我们的目的是评估瑞舒伐他汀积极降脂治疗对斑块消退和不稳定的影响。计划接受择期经皮冠状动脉介入治疗且血管造影黄斑为2级或更高的37例稳定型心绞痛或无症状性心肌缺血患者被随机分配至大剂量(H组,20 mg /天,n = 18)或低剂量剂量(L组,2.5毫克/天,n = 19)瑞舒伐他汀治疗48周。通过血管镜检查将黄色斑块从0(白色)到3(亮黄色)的4点等级进行分级,并通过血管内超声确定5至15 mm长的斑块的斑块体积。在基线和48周后,由对瑞舒伐他汀不知情的研究人员评估颜色和体积。剂量,并在2个给药组之间进行比较。 H组的低密度脂蛋白胆固醇水平从130.3 +/- 25.5 mg / dl降至61.7 +/- 16.5 mg / dl(-50 +/- 19%:高强度),而从130.9 +/- 28.5 mg / dl至89.7 +/- 29.0 mg / dl(-30 +/- 22%:中等强度)。 L组(平均值+/- SD,p <0.001)。 48周后,H组黄斑的平均颜色等级从2.0降至1.5(p <0.001),而L组从2.0降至1.6(p <0.001)。 H组的斑块体积显着降低,但L组没有显着降低。H组的斑块体积变化百分比显着大于L组(p = 0.005)。总之,大剂量和小剂量瑞舒伐他汀均可增加斑块稳定性。然而,大剂量瑞舒伐他汀在诱导斑块体积消退方面比低剂量瑞舒伐他汀更有效。 (C)2016 Elsevier Inc.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号